CalciMedica, Inc. (NASDAQ:CALC) Short Interest Up 112.3% in October

CalciMedica, Inc. (NASDAQ:CALC) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 72,600 shares, an increase of 112.3% from the October 15th total of 34,200 shares. Currently, 1.4% of the shares of the company are sold short. Based on an average daily volume of 52,900 shares, the short-interest ratio is presently 1.4 days.

Insider Activity at CalciMedica

In other CalciMedica news, CEO A. Rachel Leheny bought 20,000 shares of the company’s stock in a transaction on Friday, November 1st. The shares were bought at an average price of $3.75 per share, for a total transaction of $75,000.00. Following the transaction, the chief executive officer now owns 130,926 shares of the company’s stock, valued at approximately $490,972.50. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Eric W. Roberts purchased 53,333 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were acquired at an average price of $3.75 per share, with a total value of $199,998.75. Following the purchase, the insider now directly owns 164,706 shares of the company’s stock, valued at $617,647.50. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO A. Rachel Leheny purchased 20,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were purchased at an average cost of $3.75 per share, with a total value of $75,000.00. Following the purchase, the chief executive officer now directly owns 130,926 shares in the company, valued at approximately $490,972.50. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 312,944 shares of company stock worth $1,172,910 over the last 90 days. Company insiders own 41.55% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Atria Investments Inc grew its position in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,503 shares of the company’s stock after buying an additional 15,296 shares during the period. Atria Investments Inc owned about 0.25% of CalciMedica worth $117,000 as of its most recent SEC filing.

CalciMedica Stock Down 2.3 %

Shares of CalciMedica stock traded down $0.08 during trading hours on Wednesday, hitting $3.41. 83,812 shares of the company’s stock traded hands, compared to its average volume of 36,555. CalciMedica has a twelve month low of $2.68 and a twelve month high of $8.38. The stock has a 50 day simple moving average of $4.15 and a 200-day simple moving average of $4.57.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. As a group, equities analysts forecast that CalciMedica will post -2.21 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price target on CalciMedica from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, November 4th.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.